Express subcutaneous IgG infusions: decreased time of delivery with maintained safety.
The aims of the study were to evaluate the safety and feasibility of weekly express subcutaneous replacement IgG self-infusions (E-SCIG, 35 mL/h/syringe driver) in 50 patients and to evaluate their perceptions of the therapy. A total of 4900 E-SCIG infusions at separate infusion sites were given on 1228 treatment occasions. The most commonly reported local tissue reactions were swelling (n = 37), redness (n = 25), and soreness (n = 24). A majority of these patients reported the local reactions as less intense or unchanged compared to those arising from rapid SCIG (20 mL/h) infusions. The patients reported a median score of 16 (visual analogue scale, VAS; 1, not troublesome at all) regarding their overall perceptions of the local reactions. They were positive toward the home therapy regime (median VAS score 96; 100, very positive) and anxious to continue with the E-SCIG infusions (median VAS score 98; 100, very anxious). The E-SCIG method seems to be safe, with few pronounced local reactions, and is appreciated by the patients. Express delivery could also potentially facilitate IgG delivery in a wide variety of diseases, such as autoimmune and autoimmune-like conditions of a neurological or rheumatological character.
Hansen
S
S
Immunodeficiency Unit, Department of Immunology, Microbiology and Pathology, Section of Clinical Immunology, Karolinska Institutet, Huddinge University Hospital, Stockholm, Sweden.
Gustafson
R
R
Smith
C I E
CI
Gardulf
A
A
D000279:Administration, Cutaneous; D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage* / Q000009:adverse effects; D007153:Immunologic Deficiency Syndromes / Q000628:therapy; D008297:Male; D008875:Middle Aged; D010147:Pain Measurement; D010349:Patient Compliance; D013997:Time Factors
D007074:Immunoglobulin G